The anti-sweat device has been on the market since receiving its medical device license from Health Canada in October 2018. Since this time, Dermadry has received daily inquiries regarding the availability of its device in the United States, signaling a major need for this type of treatment in the U.S., which was not previously adequately met. The news of the FDA clearance of Dermadry’s anti-sweat device puts an end to these inquiries, as the presale of the device was made available to U.S. residents on the 26th of February.
Dermadry was developed by a team of hyperhidrosis sufferers and is now the best-selling iontophoresis machine worldwide. Dermadry is proud to add its FDA clearance to its long list of certifications and compliances worldwide, which also includes a license from the Australian Therapeutic Goods Administration (TGA), as the company has prioritized safety and efficiency since its early development stages.
Dermadry follows the strictest safety standards and has been recognized as the iontophoresis machine with the most certifications and compliances globally. Some of these certifications include a seal of approval of their products from both the Canadian Podiatric Medical Association (CPMA) and L’Ordre des Podiatres du Québec.
Hyperhidrosis is a medical condition that causes sweating 4-5 times in excess of the body’s thermoregulation needs. It is reported estimated to affect over 5% of the global population or 1 in 20 people. This reported prevalence is thought to be a much lower figure than the actual number of people affected, as hyperhidrosis is a misunderstood and underreported condition. Those affected often do not seek medical attention and often live their life in discomfort and embarrassment due to shame or simple lack of awareness, despite hyperhidrosis being a highly treatable condition.
Iontophoresis is a natural, non-invasive, drug-free, and needle-free treatment option for hyperhidrosis patients. Dermadry is proud to offer an all-in-one device that has been developed to target and treat excessive sweating of the hands, feet, and underarms.
This home-use new device facilitates treatment by allowing patients to treat excessive sweating from home using only tap water and create their own treatment schedule to fit their lifestyle and needs. It eliminates the need for painful and invasive procedures, as well as recurrent costs and clinic visits.
To celebrate Dermadry’s launch in the United States, the Canadian company has partnered with U.S. telemedicine provider SkyMD, which enables patients to receive a diagnosis and prescription online. As all iontophoresis machines require a prescription in the U.S., this service enables users to get a dermatology consultation online, making it easier and more convenient than ever before to get the required prescription. More information about this partnership can be found here.
This is the first of many exciting collaborations the company is working on. In the upcoming months, Dermadry will be bringing its device to medical conferences and events across the U.S., furthering its mission to raise awareness of hyperhidrosis and iontophoresis treatment. This furthers their mission to raise awareness of hyperhidrosis and iontophoresis treatment, as they have done in their most recent visit at Arab Health, the biggest healthcare conference in the Gulf Cooperation Council (GCC).
Going forward, the ambitious company is already looking to obtain more worldwide certifications, in order to make their device available to more people globally. Dermadry is excited to be entering the U.S. market and helping residents across the country obtain the dryness, comfort, and confidence they deserve.